Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards Redesigns PARTNER Trial, Pushes Back Sapien Approval Timeline

This article was originally published in The Gray Sheet

Executive Summary

Edwards Lifesciences has reached a verbal agreement with FDA on an amended design for the PARTNER trial of its Sapien transcatheter aortic valve, the company announced during its Dec. 7 2007 investor conference

You may also be interested in...



Medtronic Catapults Into Transcatheter Valve Market With Billion-Dollar Buys

Medtronic will enter the high-growth, minimally invasive aortic heart valve market through two acquisitions worth more than $1 billion

Medtronic Catapults Into Transcatheter Valve Market With Billion-Dollar Buys

Medtronic will enter the high-growth, minimally invasive aortic heart valve market through two acquisitions worth more than $1 billion

Analyst Bursts Edwards’ Bubble On PARTNER Percutaneous Valve Trial

An analyst raised doubts last week about Edwards Lifesciences' ability to gain approval for all studied indications in its closely watched U.S. trial for the Sapien percutaneous aortic valve

Related Content

UsernamePublicRestriction

Register

MT025594

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel